Slide background
TAmiRNA – Triple A research and development of RNA diagnostics and therapeutics
Slide background
TAmiRNA – Introducing personalized medicine to Aging
Slide background
TAmiRNA – Harnessing the power of microRNAs for development of innovative diagnostic and therapeutic tools
Slide background
TAmiRNA – Helping to enhance your stability and quality of life with advanced age

microRNAs and osteoporosis

osteoporosis

Osteoporosis is one of the most common chronic diseases worldwide and causes more than 8.9 million fractures annually, resulting in an osteoporotic fracture every three seconds. Osteoporosis is estimated to affect 200 million women globally (1).

After the onset and during the progression of osteoporosis frequently experience no or very few symptoms. However, the adverse outcome of osteoporosis are so-called fragility-fractures, which occur after low-trauma accidents and cause severe socio-economic burden for both patients and healthcare.

Primary osteoporosis is the most frequent form (95%) of osteoporosis and affects women at or after menopause. The effective prevention of primary osteoporosis related fractures depends on efficacious therapeutic treatments as well as precise diagnostic tools that are able to capture fracture risk at an early stage of the disease.

One mission of TAmiRNA is to increase awareness of the importance of early diagnosis of osteoporosis.

diagnosis of osteoporosis – gold-standard

The state-of-the-art for diagnosis of osteoporosis is the assessment of bone mineral density by Dual-X ray absorptiometry (DXA) or the WHO-FRAX score. Although both tools have clinical utility and are routinely applied they face major limitations, especially when contributing factors such as diabetic osteopathy are present. Bone turnover markers such as serum C-terminal telopeptide of type I collagen (s-CTX) can be used for monitoring of anti-osteoporotic treatments, however, their utility for predicting fracture-risk has not been validated.

Novel biomarkers are therefore desirable, which can alone or in combination with existing biomarkers provide a better understanding of bone strength and fracture risk in patients. 

microRNA biomarkers for osteoporosis

The clinical utility of biomarkers should be evaluated on the basis of three characteristics (2)

  • measurability
  • validated biology
  • decision support

measurability

Circulating microRNAs can be quantified in serum/plasma samples using quantitative PCR. The method is reliable and can undergo technical validation. However, in order to be successful a well-characterized and standardized protocol must be used. TAmiRNA has developed a robust workflow and offers qPCR kits together with software solutions for circulating microRNA analysis.

validated biology

Numerous studies have by now validated that microRNAs are regulated during bone formation and resorption and therefore play an important role in bone homeostasis. In the following a few examples for so-called “osteomiRs” are given: 

  • miR-31-5p inhibits bone formation via Frizzled-3, Osterix, and SATB2; miR-31-5p is induced by RANKL and promotes osteoclast formation (3-6)
  • miR-29b-3p promotes bone formation and extracellular matrix remodelling by regulating collagen synthesis (7-10)
  • miR-335 promotes bone formation by silencing WNT inhibitor DKK-1 (11)
  • miR-214 inhibits bone formation via ATF4 and is down-regulated in osteoporotic bone (12) 

decision support

TAmiRNA has conducted several clinical studies to explore the diagnostic and prognostic performance of circulating microRNAs in osteoporosis. It could be shown that microRNAs alone or in combination with DXA or FRAXTM provide excellent discrimination between high and low-risk patient subgroups in postmenopausal, diabetic as well as male idiopathic osteoporosis (13).

The osteomiRTM kit enables the simple and robust detection of osteomiRs in serum samples. The osteomiR app streamlines and standardized the analysis and interpretation of qPCR data.  

 

further reading

  1. Hernlund E, Svedbom a, Ivergård M, Compston J, Cooper C, Stenmark J, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 2013;8:136.
  2. Hackl M, Heilmeier U, Weilner S, Grillari J. Circulating microRNAs as novel biomarkers for bone diseases – Complex signatures for multifactorial diseases? Mol Cell Endocrinol 2016;432:83–95.
  3. Weilner S, Schraml E, Wieser M, Messner P, Schneider K, Wassermann K, et al. Secreted microvesicular miR-31 inhibits osteogenic differentiation of mesenchymal stem cells. Aging Cell 2016.
  4. Mizoguchi F, Murakami Y, Saito T, Miyasaka N, Kohsaka H. miR-31 controls osteoclast formation and bone resorption by targeting RhoA. Arthritis Res Ther 2013;15:R102.
  5. Xie Q, Wang Z, Bi X, Zhou H, Wang Y, Gu P, et al. Effects of miR-31 on the osteogenesis of human mesenchymal stem cells. Biochem Biophys Res Commun 2014;446:98–104.
  6. Deng Y, Wu S, Zhou H, Bi X, Wang Y, Hu Y, et al. Effects of a miR-31, Runx2, and Satb2 regulatory loop on the osteogenic differentiation of bone mesenchymal stem cells. Stem Cells Dev 2013;22:2278–86.
  7. Franceschetti T, Kessler CB, Lee S-K, Delany AM. miR-29 Promotes Murine Osteoclastogenesis by Regulating Osteoclast Commitment and Migration. J Biol Chem 2013;288:33347–60.
  8. Kapinas K, Kessler C, Ricks T, Gronowicz G, Delany AM. miR-29 Modulates Wnt Signaling in Human Osteoblasts through a Positive Feedback Loop. J Biol Chem 2010;285:25221–31.
  9. Li Z, Hassan MQ, Jafferji M, Aqeilan RI, Garzon R, Croce CM, et al. Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation. J Biol Chem 2009;284:15676–84.
  10. Kapinas K, Kessler CB, Delany AM. miR-29 Suppression of Osteonectin in Osteoblasts: Regulation During Differentiation and by Canonical Wnt Signaling. J Cell Biochem 2009;108:216–24.
  11. Zhang J, Tu Q, Bonewald LF, He X, Stein G, Lian J, et al. Effects of miR-335-5p in modulating osteogenic differentiation by specifically downregulating Wnt antagonist DKK1. J Bone Miner Res 2011;26:1953–63.
  12. Wang X, Guo B, Li Q, Peng J, Yang Z, Wang A, et al. miR-214 targets ATF4 to inhibit bone formation. Nat Med 2013;19:93–100.
  13. Heilmeier U, Hackl M, Skalicky S, Weilner S, Schroeder F, Vierlinger K, et al. Serum microRNAs Are Indicative of Skeletal Fractures in Postmenopausal Women with and without Type 2 Diabetes and Influence Osteogenic and Adipogenic Differentiation of Adipose-Tissue Derived Mesenchymal Stem Cells In Vitro. J Bone Miner Res 2016. doi:10.1002/jbmr.2897.

 
 

Click here for our personalized offer!